Insider Buying: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Purchases 122,221 Shares of Stock

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) CFO Gordon Dunn bought 122,221 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was bought at an average cost of $0.45 per share, with a total value of $54,999.45. Following the completion of the purchase, the chief financial officer now owns 151,077 shares of the company’s stock, valued at approximately $67,984.65. The trade was a 423.55 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Quoin Pharmaceuticals Trading Down 1.6 %

Shares of Quoin Pharmaceuticals stock traded down $0.01 during midday trading on Friday, reaching $0.55. The company had a trading volume of 553,804 shares, compared to its average volume of 1,118,553. The stock has a fifty day simple moving average of $0.68 and a 200 day simple moving average of $0.63. Quoin Pharmaceuticals, Ltd. has a 1-year low of $0.43 and a 1-year high of $6.18. The company has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.14 and a beta of 1.79.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.